AlzeCure Pharma AB

AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in innovative drug research with a primary focus on neuroscience and Alzheimer’s disease. The company is listed on Nasdaq First North Premier Growth Market and is developing candidates based on the three research platforms, NeuroRestore, Alzstatin and Painless. The NeuroRestore platform comprises symptom-relieving drug candidates while Alzstatin includes disease modifying and preventive drug candidates. A diversified portfolio of drug candidates that act on central signaling pathways in the brain also opens up for other indications such as cognitive dysfunctions in traumatic brain injury (TBI), sleep apnea and Parkinson’s disease, as well as depression. The company also have projects in the field of pain. For further information visit www.alzecurepharma.com

Ferring Pharmaceuticals Inc. USA

- Annual sales of USD 700 million. Headcount: 750.
- Responsibilities: Managing the development of all long & short term plans, tracking execution & optimizing the operational effectiveness of the organization, incl MSLs.  
- Reorganization of the Medical Affairs department to be more customer centric, strategic & agile.
- Improved productivity within the department & therapeutic areas by over 30%.

Therapeutic areas I'm engaged in: Endocrinology, Gastroenterology, Reproductive health, Obstetrics, Urology, Oncology, and Orthopedics,

US Head of Planning and Operational Effectiveness, Medical Affairs

Ferring Pharmaceuticals Inc, USA

- Annual sales of USD 70 million. Headcount: 190. 5 direct reports.
- Responsibilities: Led the sales & marketing organizations, including driving business development initiatives.
- Successfully reorganized the sales organization & generated increasing growth & cost savings; Decreased the total sales force by 34%; Implemented key account team; Launched a “sales force effectiveness program”; Focused marketing spend, decreased spend by 50%. 
- Accelerated urology sales growth from 7 to 14% & improved profits.

Head of Business Units, Urology/Oncology and Gastroenterology, Sr Director

- Responsibilities: Led the sales & marketing organizations (90 individuals), including driving business development initiatives. 
- Re-organized and re-staffed the sales leadership and the marketing department, enhancing the cooperation between the two groups.
- Managed the launch preparations of new drugs as well as a new therapeutic area, and acquired a new pipeline drug. 
- Increased sales development by 50% to double digit growth, and improved the personnel retention by 25%.

Head of Business Unit, Urology & Oncology, Sr Director

- Initiated & led project to optimize sales & marketing resource utilization, & increasing insights on what was driving success. Done by collecting & organizing sales, activity, marketing & market research data through a central database to do multivariate & predictive analytics. 
- Optimized resource utilization & activities to drive sales, on an annual basis, by an additional 12%.

Head of Project Insight – Marketing & Sales Optimization Through Advanced Analytics

Ferring Pharmaceuticals

RESPONSIBILITIES: Led the development of Ferring’s global road map for digital marketing goals, strategies & tactics, as well as global policies, SOPs & guidelines, (e.g. social media activities, monitoring & engagement), and global educational initiatives on digital.
- Founded & led the global “Ferring Digital Marketing Academy”, developing its concepts, plans, activities & global task forces.
- Organized & led annual global & regional meetings, workshops & webinars to educate, discuss & share the “best practice” on digital strategies and initiatives.

Global Lead and initiator of the Ferring Digital Marketing Academy

RESPONSIBILITIES: Globally responsible for developing & leading the execution of the global commercial strategies & activities for Minirin®, as well as for Testim® in Europe; Led the global life cycle management & supporting business development. 
- Led a global launch team, preparing the launch of a new drug, crafting both the global & US launch plan.
- Accelerated Minirin® sales by 50% to a CARG of 8%, & successfully managed generic competition.

Global Strategic Brand Lead, Urology & Oncology

- Responsibilities: Led the sales & marketing department, & business development, with 7 direct reports. Products: Minirin®, Firmagon® Testim® and Decapeptyl®
-Established a more targeted customer approach, investing heavier in Key Opinion Leader cooperation projects & a coordinated multichannel customer interactions approach with more non-personal & digital initiatives.
-Accelerated sales beyond the business plan, fighting off generic competition for Minirin®, keeping a market share of 98% for the product without lowering price.

Business Unit Manager; Urology & Endocrinology

- Responsibilities: Led the sales & marketing department, & business development, with 5 direct reports. Products: Menopur®, Tractocile, Propess®/Cervidil®, Norprolac®
- Improved the sales force productivity through “sales force effectiveness” initiatives, strengthened relationships & cooperation with key opinion leaders, generating more external & visible product ambassadors.
- Accelerated the sales of the company’s key product, Menopur®, beyond business plan, increasing sales & volume market shares from 7 to 21% over a three year time period.

Business Unit  Manager; Gynecology & Obstetrics

- Responsibilities: Marketing & launches in the Nordic region (Denmark, Sweden, Norway, Iceland, Finland & the Baltics), team of two regional brand managers at our Nordic HQ, coordinating activities with brand managers and key account managers in the Nordic affiliates.
- Led the planning & tactics with regards to generic products entering the Nordic desmopressin market. 
- Outperformed goal: Grew the desmopressin sales, kept 97% of our market shares, achieving better results than all other local markets where Ferring had generic competition.

Nordic Group Brand Manager; Urology, Gynecology, Obstetrics, Endocrinology

- Responsibilities: Marketing in the Nordic region & cooperating with brand managers in the local affiliates regarding Menopur®, Tractocile®, Propess/Cervidil®, Decapeptyl® & Norprolac®.
- Led the launch of the IVF drug Menopur® in the Nordic region; developed the launch plan, incl. positioning, strategies, value proposition, pricing, tactics, detailing material, & the relationships with key opinion leaders, scientific associations & patient organizations.
- Successfully launched Menopur® in the Nordic region to become the most successful Menopur® region in the world.

Nordic Brand Manager Reproductive Health, Gynaecology & Obstetrics

- Responsibilities: Marketing of the urology brands; developed the strategic & tactical plans, promotional & educational material, managed regional congresses, key opinion leader & association relationships.
- Successfully pre-launched & launched Minirin® for nocturia
- The Nordic concept for launching Minirin® became a “best practice” case for other countries & regions.

Nordic Brand Manager Urology

- Responsibilities: Launch of Minirin® for nocturia; developed the launch plan for the brand, promotional & educational material, launch activities, publications, PR, developing & managing stakeholder, including key opinion leaders & reimbursement authorities.
- Successfully launched Minirin® for nocturia, as the first country in the world, & out performed the sales goals. 
- Created major interest in the nocturia disease area, as well as for Minirin® treating the condition, & making patients seek help within health care systems.

Product Manager Urology; Sweden

Orkla Foods Sverige AB

- Responsibilities: Marketing & Advertising of Felix® frozen ready meals & canned food, incl. for driving the innovation & product development within two product categories. 
- Developed & launched a new ready meal assortment & brand for healthier ready meals “Live Well”, as well as an innovative frozen soup assortment which became, & still is, very successful.
- Worked very actively with market research to track marketing initiatives & product development, including trade marketing initiatives. 
- Successfully drove the sales beyond budget within my two categories of ready meals.

Product Manager, Ready Meals, Sweden

- Key Account Manager, sold consulting & industrial software systems for product development, industrial design, 3D construction, virtual reality visualization & data integration.
- Responsible for ABB Adtranze, ABU Garcia, & Atlas Copco.  
- Out performed my sales budgets & was awarded a member-ship in the company’s “President’s Club”; an organization for the top 5% best sales performers in the world. 
www.ptc.com

Key Account Manager for industrial product development software systems

Roche

- Responsibilities: Develop & implement marketing & sales plans, as well as promotional material & campaigns for OTC products in gastro, food supplements, dermatology, pain & wound care in the Swedish & Danish market.
- Developed trade marketing concepts and campaigns for pharmacies, including material to optimize product display & sales in the stores.
- Successfully launched Rennie®, Bepanthen® & Berroca®.

Sales rep & Field Product Manager

Swedish Royal Airforce

Officer in the Swedish Airforce

ANALYTICAL, INNOVATIVE & ENGAGING LIFE SCIENCE LEADER WITH GLOBAL EXECUTIVE SALES, MARKETING AND MEDICAL AFFAIRS EXPERIENCE.

 - Life-science professional with global experience and  strong commercial skills in sales, marketing, and digital communication, as well as in medical affairs. 
 - Proven turnaround/restructuring/change management capability and experience.
 - Delivered solid financial improvement in all assignments through engagement, innovation, growth and operational improvement. 
- Strong social and cultural skills, with open and inclusive leadership style.

The most frequently asked question I receive when I give biopharma seminars in University settings.  "How do you go from science to business?"

This is a really complex question, because it starts from motivation, and it ends with structured activity.

*  Scientists love science.  They are generally good at designing experiments that address a fundamental question and more often than not, generate a fuzzy outcome.  This drives them nutz and provokes them to do more experiments.  The process is fulfilling once you are hooked. They continue with papers accepted and grants funded. The adrenaline rush comes from discovering something never seen before. 

*  BD people are motivated to get to Docusign.   Their core activity is centered around obtaining the best terms for the company, where most anticipated profit can be made beneficially.  During this process, relational skills are paramount to keep negotiations ongoing so that parties do not walk out. The adrenaline rush comes when the deal is executed and both parties sign.  

Going from one mindset to the next is not an easy transition as scientists seek verifiable Truth in nature, whereas BD people seek relational commitment in legal form.  Totally different.

In a biopharma BD setting, scientists need to realize that being personally attached to the science underlying the business transaction is NOT conducive to mental health, and one needs some detachment to be successful. 

As an analogy, I often remark that a BD person is like realtor, you match houses to buyers and sellers, and offer the best, most strategic positioning so both parties want to sign, but you DON'T own the house for sale.  In fact, a Realtor is selling multiple houses simultaneously, and reputation is gained by how fast the sales go.

The key difference is reflected by the CV of scientists vs resumes of BD people.  As my readership are primarily scientists, it is obvious to list education, publication, and accolades.  

But in BD, the key part of a resume is the Deal Sheet.  

A Deal Sheet is analogous to a publication record, a history of executed deals one has participated in.  An accomplished BD person would have frequent deals listed and dollar amount to indicate value acumen.  Of course, just like authorship in scientific publications, one needs to be wary of degree of participation of the BD person within the team that fostered the deal.

Typically for a scientist to transition to business, it requires a change in mindset first, and then afterwards, work towards creating a Deal Sheet for their future resume that would be used to land a business job.  The easiest path to this is through working at university tech transfer departments, or through working in VC or investment / consulting firms.  

Deal Sheet resumes here:
https://lnkd.in/ePyxvJUJ

Disclaimer - Views expressed here are of the Author only

Martin Jönsson

Nina Gunke är en folkkär skådespelerska som många säkert känner igen från tv-serierna Varuhuset, Skilda världar eller julfilmsklassikern Tomten är far till alla barnen. Nu har Nina fått ett helt annat uppdrag på sitt bord, hon är nämligen ambassadör för Alzheimerfonden.
2020 drabbades Nina av Alzheimers sjukdom och gick direkt in i ett ångestfyllt mörker när hon fick beskedet, läs mer här https://lnkd.in/dTSfDu4Y


Du kan också läsa mer om Alzheimerfonden här https://lnkd.in/dzYSvYds

NEW: Universal BCI - Control Games With Your Thoughts
NONINVASIVE brain-computer interface (BCI) does not require calibration for each user, setting the stage for further BCI innovation and clinical applications!

👉  Researchers show for the first time how inter-subject transfer #learning approaches enable inexperienced users to immediately operate 
a noninvasive BCI, without the need for the standard individual calibration session/s. 

Study:
•  18 healthy participants, trained for 
•  a simple digital bar balancing and a car racing game,
•  wearing a cap packed with electrodes hooked up to a #computer.
•  Electrodes gather data by measuring signals from the #brain - and  
•  decoder interprets the information and 
     translates it into #game action.

👉  Researchers developed techniques for calibration-free BCI training
creating opportunities for widespread clinical applications, that 
may help users guide and strengthen their neural #plasticity, the ability of the brain to change and reorganize over time. 

José del R. Millán's lab works on a #wheelchair that users can drive with BCI.

🚀 These calibration-free BCI approach
will help to improve brain function and use the devices controlled by BCI to improve mobility, independence, and quality of life for people with disabilities.


PNAS Nexus | Feb 16, 2024      -- More info & links in Comments
----------------
Satyam kumar, Hussein Alawieh, Frigyes Samuel Racz, Rawan Fakhreddine, Jose del R Millan
The University of Texas at Austin, Chandra Family Department of  Electrical and Computer Engineering (Texas ECE - UT Austin ECE) , Cockrell School of Engineering, The University of Texas at Austin

#science #neuroscience #technology #future #ai #innovation #sci #neurotech #startups #cognitive #medicine #als #eeg #healthcare #precisionmedicine #healthtech #personalizedmedicine #gaming #collaboration #linkedin #news #communication #brainstimulation #neuromodulation #discovery #language #slp #healthinnovation 

#mentalhealth #disability #intervention #neurology #neuropsychology #psychology #braincomputerinterface #braininjury #tbi #rehabilitation #artificialintelligence #neurorehab #biomedical #engineering #computing

Nästa Hjärnskolan på @nyhetsmorgon TV4  är den 17 april, och fler program kommer efter det! Är det något särskilt som du vill veta om hjärnan som du vill att vi tar upp? Något du gått och funderat på hur det egentligen ligger till? Kanske är det ett ämne som intresserar även många andra i Sverige, i så fall kan vi ta med det i Hjärnskolan! 👩‍🏫🧠📺

Eli Lilly's and AstraZeneca's former head of research Dr. Jan Lundberg invests in AlzeCure and is proposed for election to its board

Professor Jan Lundberg has more than 25 years of experience from leading positions in global pharmaceutical companies, including as global head of research at Astra and then AstraZeneca (1996 - 2009) and global head of research and development at Eli Lilly (2010 - 2018). 

He has led the development of more than 200 drug candidates, including Alzheimer's and pain, with 30 approved products in several therapeutic areas. Before joining Astra, Dr. Lundberg was professor of pharmacology at the Karolinska Institute in Sweden, where he also received his PhD. He also studied medicine at the University of Gothenburg for four years and his research has resulted in over 500 publications in peer-reviewed scientific journals. 

"We are incredibly grateful and happy that Jan Lundberg both wants to become a board member and invest in AlzeCure, with the fantastic experience and knowledge he possesses. We are convinced that this will make a very positive contribution to our continued future successful development,” said Martin Jönsson, CEO of AlzeCure Pharma

Read the full press release here: https://lnkd.in/eKFhduMj

#alzecure #alzheimerfonden #redeye #avanza #nordnet #edisongroup #seb #swedbank #nordea #aktiespararna #privataaffarer #vatorsecurities #finwire

alzecurepharma.se • 3 min read

Eli Lilly's and AstraZeneca's former head of research Dr. Jan Lundberg invests in AlzeCure and is proposed for election to its board - AlzeCure Pharma

Vi har träffat AlzeCure Pharma med vd Martin Jönsson.

• Det senaste inom bolaget
• Emissionen 
• Professor Jan Lundberg

Se hela intervjun: https://lnkd.in/dEPcFsnt

Tungt namn till Alzecure: ”Fantastiskt spännande"

Han har varit global forskningschef för jättebolagen Astra Zeneca och Eli Lilly – nu kliver profilen Jan Lundberg in i Alzecure Pharma. 

Artikel: https://lnkd.in/daU4e2ZR

Pressmeddelande: 
https://lnkd.in/dXTFX9EM 

#elililly #astrazeneca #alzecure #alzheimers

lifesciencesweden.se • 1 min read

Tungt namn till Alzecure: ”Fantastiskt spännande"

AlzeCure presenterar nya data kring smärtprojektet TrkA-NAM på IASP 2024

AlzeCure meddelar idag att ett abstract om sitt prekliniska projekt TrkA-NAM mot osteoartros smärta och andra svåra smärttillstånd har accepterats för presentation vid IASP 2024 World Congress on Pain i Amsterdam den 5-9 augusti. 

Abstractet, med titeln Pharmacological Effects of ACD137, a Potent and Selective Negative Allosteric Modulator of TrkA, ska presenteras vid den globala smärtkonferensen IASP 2024 World Congress on Pain av Pontus Forsell, projektledare och Head of Discovery and Research på AlzeCure. Bland de andra författarna ingår Gunnar Nordvall, Maria Backlund, Veronica Lidell, Azita Rasti, Cristina Parrado-Fernandez, Johan Sandin och Märta Segerdahl.

Presentationen inkluderar nya prekliniska resultat som beskriver egenskaperna hos den nyligen valda läkemedelskandidaten för TrkA-NAM, ACD137. Data visar att substansen är en potent och selektiv negativ modulator av NGF/TrkA-signalering i cellbaserade analyser. Nya data i flera olika prekliniska smärtmodeller visar även på tydliga och signifikanta smärtstillande effekter av ACD137.

"Målmekanismen i projektet har en stark validering i smärta, både prekliniskt och kliniskt och vår nya läkemedelskandidat ACD137 i TrkA-NAM programmet är ett mycket bra exempel på de mycket potenta och selektiva substanser som vi tagit fram i projektet. ACD137 uppvisar mycket god smärtlindring i prekliniska modeller in vivo, och dessa nya data ger en tydlig validering av vår forsknings- och utvecklingsplattform", säger Pontus Forsell, Head of Discovery and Research på AlzeCure.

"De nya resultaten visar att ACD137 är en mycket lovande läkemedelskandidat med tydliga smärtstillande effekter. Att målmekanismen dessutom inte är kopplad till de biverkningar och beroendeproblem som observerats med opioider är förstås också viktigt för ett framtida godkännande", säger Martin Jönsson, VD för AlzeCure Pharma. ”Intresset för TrkA-NAM har även ökat ytterligare efter att Asahi Kasei nyligen inlett sin fas 2bstudie med AK-1830 mot knäledsartros, vilket validerar AlzeCures projekt, där vi tagit fram molekyler som är än mer potenta och selektiva än AK-1830”, fortsätter han.

Abstractet och postern kommer att finnas tillgängliga på AlzeCures hemsida efter presentationen (https://lnkd.in/eNnHfFj
Läs mer här: https://lnkd.in/geNN63fT
 
#alzecure #TrkANAM #nordnet #avanza #erikpenserbank #redeye #aktiespararna #swedbank #analysguiden #finwire #placera #IASP2024 #ACD137 #osteoarthritis #pain

Som före detta global forskningschef på Eli Lilly och AstraZeneca, med över 500 publicerade artiklar, är det ingen överdrift att kalla professor Jan M Lundberg för en tungviktare i branschen. Nu tar han steget in som ny ägare i AlzeCure Pharma och föreslås samtidigt till bolagets styrelse. BioStock har kontaktat AlzeCures vd Martin Jönsson för en kommentar.

biostock.se • 3 min read

Tungviktare tar steget in i AlzeCure Pharma

Läs artikeln från Dagens Industri

https://lnkd.in/dHVM7f8q

#alzecure #DI #alzheimerfonden #redeye #avanza #nordnet #edisongroup 
#seb #swedbank #nordea #aktiespararna #privataaffarer #vatorsecurities #finwire #elililly #KI #astrazeneca

Improved possibilities to stage Alzheimer's disease patient 
- Is it possible to determine the disease stage of Alzheimer's disease using just one fluid sample?
- Yes, according to a recent Nature Aging paper we can now do that using 5 key biomarkers in cerebrospinal fluid! 

Hopefully, we can soon to the same using just a single blood sample. 

Accurate staging of the disease can inform about prognosis, but even more importantly, it will likely be vital in the future when selecting the optimal disease modifying therapy for an individual patient.

https://lnkd.in/d2qPUvH2

#alzheimers #naturecommunication #alzecure #diagnostics

nature.com • 4 min read

Disease staging of Alzheimer’s disease using a CSF-based biomarker model - Nature Aging

Ett viktigt och spännande projekt som min kära kollega Tove Wiik sysslar med 💜

AlzeCure Pharma offentliggör årsredovisning för 2023
 
”Året 2023 var fortsatt positivt och händelserikt för AlzeCure Pharma. Under året presenterade vi bland annat positiva proof-of-mechanism (POM) resultat från vår kliniska fas II-studie med ACD440 mot neuropatisk smärta. Vidare valde vi en ny läkemedelskandidat i vårt Alzheimerprojekt Alzstatin. Därutöver publicerade vi också nya prekliniska data för vår kliniska läkemedelskandidat NeuroRestore ACD856, som stödjer neuroprotektiva och sjukdomsmodifierande effekter. Detta är mycket relevant för behandling av Alzheimers och andra neurodegenerativa sjukdomar. 

Vi beviljades dessutom patent för ACD856 i ytterligare territorier, såsom i Europa och Japan, vilket än mer stärker våra affärsutvecklingsmöjligheter. Vidare har vi nu också valt en läkemedelskandidat i vårt TrkA-NAM-projekt, ACD137. 

Det är motiverande och glädjande att vi håller uppe tempot och fortsätter att leverera nya data som stärker vår position”, säger Martin Jönsson, VD för AlzeCure Pharma.
 
Årsredovisningen bifogas och finns tillgänglig på bolagets hemsida, https://lnkd.in/d39EF3gE
 
#alzecure #TrkANAM #nordnet #avanza #erikpenserbank #redeye #aktiespararna #swedbank #analysguiden #finwire #placera #ACD440 #ACD137 #alzstatin #neurorestore #annualreport

Looking forward to the coming webinar on developing drugs for depression

xtalks.com • 1 min read

Going Global: Bringing Drugs for Depression to Market in the US and EU

What We Can Learn From The Happiest Country in the World. 

For the seventh year running Finland has just been declared the world’s happiest country by the World Happiness Report, launched in 2012 to promote the sustainable development goals of the United Nations (un). Those surveyed were asked to evaluate their lives on a scale of one to ten, with ten the highest. While Scandinavian countries as usual occupied the top spots, both America and Germany fell out of the top 20. 

Overall, European countries dominated the rankings; in particular, the Nordic countriesFinland, Denmark, Iceland, Sweden, and Norway all retained spots in the top 10. 

Read de full article or the report: https://lnkd.in/dPaJABVz.

economist.com • 2 min read

The secret behind the world’s happiest country

Tony’s Chocolate. - An inspiring business initiative worth supporting, not only for the great taste. 

#tonys #chocolate #esg

youtube.com

We Accidentally Started A Chocolate Company — Now It Brings In $162 Million A Year

Racket ball players live longer ...

Learn more at Harvard Health: https://lnkd.in/dRvbUaan 

https://lnkd.in/dPDuSegh

#racketball #alzecure #brainhealth #longevity

Taplio

Martin Jönsson's Linkedin Analytics

Martin Jönsson

What is Martin talking about?

Martin Jönsson's Best Posts (last 30 days)

Want to drive more opportunities from LinkedIn?

Taplio

.css-1jgreyo{background-image:linear-gradient(284deg, rgba(39,43,72,1) 0%, rgba(33,47,183,1) 100%);color:transparent;-webkit-background-clip:text;background-clip:text;}Martin Jönsson's Linkedin Analytics

Martin Jönsson

What is Martin talking about?

Martin Jönsson's Best Posts .css-qqfgvy{font-size:var(--chakra-fontSizes-md);}(last 30 days)

Want to drive more opportunities from LinkedIn?

Martin Jönsson's Linkedin Analytics

Martin Jönsson's Best Posts (last 30 days)